- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05479773
Safety and Usability of the LUMENA Non-invasive Ventilation Mask
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
20 participants will be included in the study. The number of patients for each group is 5.
The trial is, a crossover trial, as all participants go through every one of the trial conditions, albeit in a different order, and thus every trial condition will have results of 20 patients in it eventually.
Prior to patient treatment, the subject will be informed about the study and potential risks, and will be givin written informed consent.
Prior to every inhalation and particle sampling, a baseline sample will be taken to filter possible carryovers from previous sampling.
Demographics including age, sex, DOB, height, weight and body mass index. Past medical history including smoking status, co-morbid conditions and medication use.
Vital signs before, during and after non-invasive ventilation: heart rate, respiratory rate, Tidal volume, oxygen saturation, Mode of ventilation, peak inspiratory pressure, pressure support, Ventilator type and model, Trigger sensitivity, Fio 2%, PEEP, blood pressure (invasive and/or non-invasive) and temperature.
Electrocardiogram (ECG) diagrams before and after use. Arterial blood\ Venous blood gas analysis for O2, CO2, pH and HCO3 as well as serum Lactate levels before, during and after non-invasive ventilation. A maximum of 20 ml of blood will be collected from each patient.
Room aerosol particle concertation in sizes 0.3, 0.5, 1.0 and 2.5µ. Symptoms and signs during use of non-invasive ventilation (e.g. diaphoresis, anxiety).
Estimation of patient preference of the mask - the question shall be phrased thusly: In a Which mask do you prefer? Estimation of staff comfort (an analog 1-5 scale as well as recording of verbal comments). - the question shall be phrased thusly: In a scale of 1-5, 1 being very uncomfortable to use and 5 being very comfortable, to use how would you rate the mask? Estimation of staff use - the question shall be phrased thusly: Which mask do you prefer? Estimation of patient comfort - the question will be directed to the staff member. (an analog 1-5 scale as well as recording of verbal comments) - the question shall be phrased thusly: In a scale of 1-5, 1 being very uncomfortable to use and 5 being very comfortable to use, how would you rate the patient's feeling with the experimental mask? Device related AE's will be reported by number, type, seriousness, severity and duration. All device and treatment related AEs will be captured, regardless of severity.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nadav Nahmias, Mr
- Phone Number: +972-528512371
- Email: Nadav@inspirlabs.com
Study Contact Backup
- Name: Tal Shachar, Miss
- Phone Number: +972-525308408
- Email: Tal@inspirlabs.com
Study Locations
-
-
-
Tel Aviv, Israel, 6423906
- Recruiting
- Tel Aviv Sourasky Medical Center, Ichilov
-
Contact:
- Yoel Angel, Mr
- Phone Number: +972-544662007
-
Principal Investigator:
- Nimrod Adi, Mr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female adults, aged 18 years and over.
- Suffering from hypoxemic and/or hypercarbic respiratory failure requiring non-invasive ventilation and selected by medical staff to use CPAP or BiPAP.
- Fully concious (Glasgow Coma Scale 14-15) and able to cooperate with non-invasive ventilation.
- Able to provide informed consent to participate in the study.
- Have an active arterial line in place for arterial blood sampling (arterial lines will not be placed for the sole purpose of the study). Alternatively, IV line can be used.
Exclusion Criteria:
- Age < 18 years.
- Pregnancy.
- Respiratory failure due to non-pulmonary pathology.
- Presence of a contraindication to the use of non-invasive ventilation or an absolute indication for invasive ventilation.
- Presence of a facial deformity, heavy beard or moustache which prevents a good seal between the mask and the face.
- Hemodynamic instablity.
- Severe upper gastrointestinal bleeding.
- Chest trauma.
- Claustrophobia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Group A
Treatment order: 1) Standard NIV mask ; 2) Lumena mask without suction ; 3) Lumena mask with suction. |
The hospital standered NIV mask
aerosol-reducing mask
|
Other: Group B
Treatment order: 1) Standard NIV mask ; 2) Lumena mask with suction ; 3) Lumena mask without suction. |
The hospital standered NIV mask
aerosol-reducing mask
|
Other: Group C
Treatment order: 1) Lumena mask without suction ; 2) Lumena mask with suction ; 3) Standard NIV mask. |
The hospital standered NIV mask
aerosol-reducing mask
|
Other: Group D
Treatment order: 1) Lumena mask with suction ; 2) Lumena mask without suction ; 3) Standard NIV mask. |
The hospital standered NIV mask
aerosol-reducing mask
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SPO2
Time Frame: During the 30 minutes before starting the ventilation
|
Precentage of SPO2 before ventilation
|
During the 30 minutes before starting the ventilation
|
SPO2
Time Frame: Every 20 minutes during ventilation
|
Precentage of SPO2 during ventilation
|
Every 20 minutes during ventilation
|
SPO2
Time Frame: Up to 30 minutes post ventilation
|
Precentage of SPO2 post ventilation
|
Up to 30 minutes post ventilation
|
pO2
Time Frame: During the 30 minutes before starting the ventilation
|
mmHg of PO2 before ventilation
|
During the 30 minutes before starting the ventilation
|
pO2
Time Frame: Every 20 minutes during ventilation
|
mmHg of PO2 during ventilation and post ventilation
|
Every 20 minutes during ventilation
|
pO2
Time Frame: Up to 30 minutes post ventilation
|
mmHg of PO2 post ventilation
|
Up to 30 minutes post ventilation
|
pCO2
Time Frame: During the 30 minutes before starting the ventilation
|
pCO2 before ventilation measured in mmHg
|
During the 30 minutes before starting the ventilation
|
pCO2
Time Frame: Every 20 minutes during ventilation
|
pCO2 during ventilation measured in mmHg
|
Every 20 minutes during ventilation
|
pCO2
Time Frame: Up to 30 minutes post ventilation
|
pCO2 post ventilation measured in mmHg
|
Up to 30 minutes post ventilation
|
pH
Time Frame: During the 30 minutes before starting the ventilation
|
logarithmic units of pH before ventilation
|
During the 30 minutes before starting the ventilation
|
pH
Time Frame: Every 20 minutes during ventilation
|
logarithmic units of pH during ventilation
|
Every 20 minutes during ventilation
|
pH
Time Frame: Up to 30 minutes post ventilation
|
logarithmic units of pH post ventilation
|
Up to 30 minutes post ventilation
|
HCO3
Time Frame: During the 30 minutes before starting the ventilation
|
HCO3 before ventilation measured in mEq/L
|
During the 30 minutes before starting the ventilation
|
HCO3
Time Frame: Every 20 minutes during ventilation
|
HCO3 during ventilation measured in mEq/L
|
Every 20 minutes during ventilation
|
HCO3
Time Frame: Up to 30 minutes post ventilation
|
HCO3 post ventilation measured in mEq/L
|
Up to 30 minutes post ventilation
|
Serum Lactate
Time Frame: During the 30 minutes before starting the ventilation
|
Serum Lactate before ventilation measured in mmol/Lit
|
During the 30 minutes before starting the ventilation
|
Serum Lactate
Time Frame: Every 20 minutes during ventilation
|
Serum Lactate during ventilation measured in mmol/Lit
|
Every 20 minutes during ventilation
|
Serum Lactate
Time Frame: Up to 30 minutes post ventilation
|
Serum Lactate post ventilation measured in mmol/Lit
|
Up to 30 minutes post ventilation
|
Respiratory Rate
Time Frame: during ventilation
|
Measuring of Respiratory Rate in breaths per minute, during ventilation
|
during ventilation
|
Adverse Events
Time Frame: From date of study randomization until the end of treatment per each patient, up to 30 min post ventilation
|
Number of patients related Adverse Events as assessed by CTCAE v5.0
|
From date of study randomization until the end of treatment per each patient, up to 30 min post ventilation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Room aerosol concentration
Time Frame: Before ventilation and during ventilation
|
Room aerosol concentration during usage of the Lumena for particle 0.3, 0.5, 1.0 and 2.5 Microns in units of parts per cubic meter of air
|
Before ventilation and during ventilation
|
Use comfort
Time Frame: Up up 1 hour post ventilation
|
Patient assesment of use comfort of the worn mask, in units of 1 to 5 with 5 being the highest.
|
Up up 1 hour post ventilation
|
Use comfort
Time Frame: Up up 1 hour post ventilation
|
Staff member assesment of use comfort of the worn mask, in units of 1 to 5 with 5 being the highest.
|
Up up 1 hour post ventilation
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nimrod Adi, Mr, Head of ICU
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0818-21-TLV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Failure
-
Poitiers University HospitalRecruitingAcute Respiratory Failure | Hypoxemic Respiratory FailureFrance
-
Catholic University of the Sacred HeartFisher and Paykel HealthcareCompletedWeaning Failure | Acute Respiratory FailureFrance, Greece, Italy, Spain
-
Hemovent GmbHMAXIS Medical, LLCActive, not recruitingRespiratory Failure | Cardiac Failure | Cardio-Respiratory FailureGermany
-
Efficacy Care R&D LtdMemorial Hermann Hospital; CRG Medical, Inc.UnknownShock | Shock, Septic | Respiratory Failure | Respiratory Distress Syndrome | Shock, Cardiogenic | Acute Cardiac Failure | Acute Respiratory Failure | Acute Kidney Failure | Multi Organ Failure | Respiratory Arrest | Acute Respiratory Failure With Hypoxia | Acute Respiratory Failure Requiring Reintubation | Acute... and other conditionsUnited States
-
Hospital Clinic of BarcelonaCompletedHypercapnic Respiratory Failure | Hypoxemic Respiratory FailureSpain
-
UPECLIN HC FM Botucatu UnespUnknownExtubation Failure | Acute Respiratory Failure Post ExtubationBrazil
-
Siriraj HospitalRecruitingAcute Hypoxemic Respiratory Failure | Acute Hypercapnic Respiratory FailureThailand
-
Fisher and Paykel HealthcareCentre hospitalier de l'Université de Montréal (CHUM); Institut universitaire...Not yet recruitingAcute Hypoxemic Respiratory Failure | Acute Hypercapnic Respiratory Failure
-
Hospital Sao JoaoCompletedVentilatory Failure | Post-extubation Failure | Persistent Weaning Failure | Secretion Encumbrance | Weak CoughPortugal
-
University Hospital, AngersNot yet recruitingCardio-Respiratory FailureFrance
Clinical Trials on Standard NIV mask
-
Children's Hospital Medical Center, CincinnatiCompletedSleep Apnea | Pediatric Sleep ApneaUnited States
-
Sultan Qaboos UniversityTerminatedAcute Respiratory Distress Syndrome Caused by COVID-19Oman
-
Emory UniversityCompletedRapid Sequence IntubationUnited States
-
Ahmed talaat ahmed alyAin Shams UniversityCompletedPulmonary FunctionEgypt
-
University of Campania "Luigi Vanvitelli"CompletedObesity | Postoperative Respiratory DistressItaly
-
National University Health System, SingaporeTerminatedChronic Obstructive Pulmonary Disease (COPD) | Type 2 Respiratory FailureSingapore
-
University Hospital, MontpellierUnknownSurgery | Acute Respiratory Failure | Trauma to the AbdomenFrance
-
Columbia UniversityALS AssociationTerminatedAmyotrophic Lateral Sclerosis (ALS)United States
-
Centre Hospitalier Universitaire, AmiensCompletedENT Cancer ScreeningFrance
-
ResMedRoyal Brompton & Harefield NHS Foundation TrustCompletedNeuromuscular Disease | Chest Wall Disorder | Nocturnal HypoventilationUnited Kingdom